Stay updated with breaking news from Cancer Imaging Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Durvalumab plus concurrent transarterial chemoembolization followed by durvalumab with bevacizumab resulted in a significant improvement in PFS over TACE alone in patients with hepatocellular carcinoma who are eligible for embolization, meeting the primary end point of the phase 3 EMERALD-1 trial.
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
The global portable medical devices market is projected to expand at a CAGR of 10.7% during the forecast period. The market is estimated to generate market
Date Time Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment Reston, VA-Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called 18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy. Nearly two...